Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Teva
US Army
UBS
Citi
Healthtrust
Argus Health
AstraZeneca
Fish and Richardson

Generated: September 20, 2018

DrugPatentWatch Database Preview

Merlion Pharms Gmbh Company Profile

« Back to Dashboard

What is the competitive landscape for MERLION PHARMS GMBH, and when can generic versions of MERLION PHARMS GMBH drugs launch?

MERLION PHARMS GMBH has one approved drug.

There are three US patents protecting MERLION PHARMS GMBH drugs.

Summary for Merlion Pharms Gmbh
US Patents:3
Tradenames:1
Ingredients:1
NDAs:1

Drugs and US Patents for Merlion Pharms Gmbh

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merlion Pharms Gmbh XTORO finafloxacin SUSPENSION/DROPS;OTIC 206307-001 Dec 17, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial
Merlion Pharms Gmbh XTORO finafloxacin SUSPENSION/DROPS;OTIC 206307-001 Dec 17, 2014 RX Yes Yes 9,119,859 ➤ Try a Free Trial ➤ Try a Free Trial
Merlion Pharms Gmbh XTORO finafloxacin SUSPENSION/DROPS;OTIC 206307-001 Dec 17, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial
Merlion Pharms Gmbh XTORO finafloxacin SUSPENSION/DROPS;OTIC 206307-001 Dec 17, 2014 RX Yes Yes 9,504,691 ➤ Try a Free Trial Y ➤ Try a Free Trial
Merlion Pharms Gmbh XTORO finafloxacin SUSPENSION/DROPS;OTIC 206307-001 Dec 17, 2014 RX Yes Yes 8,536,167 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for Merlion Pharms Gmbh

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merlion Pharms Gmbh XTORO finafloxacin SUSPENSION/DROPS;OTIC 206307-001 Dec 17, 2014 6,133,260 ➤ Try a Free Trial
Merlion Pharms Gmbh XTORO finafloxacin SUSPENSION/DROPS;OTIC 206307-001 Dec 17, 2014 6,432,948 ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

International Patents for Merlion Pharms Gmbh Drugs

Country Document Number Estimated Expiration
Russian Federation 2012103458 ➤ Try a Free Trial
Japan 5784012 ➤ Try a Free Trial
European Patent Office 2448587 ➤ Try a Free Trial
European Patent Office 2928475 ➤ Try a Free Trial
Argentina 093813 ➤ Try a Free Trial
Japan 2015134827 ➤ Try a Free Trial
Country Document Number Estimated Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Dow
Citi
Cantor Fitzgerald
Baxter
Federal Trade Commission
Accenture
Covington
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.